252 related articles for article (PubMed ID: 9440758)
1. ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy.
Metzger R; Leichman CG; Danenberg KD; Danenberg PV; Lenz HJ; Hayashi K; Groshen S; Salonga D; Cohen H; Laine L; Crookes P; Silberman H; Baranda J; Konda B; Leichman L
J Clin Oncol; 1998 Jan; 16(1):309-16. PubMed ID: 9440758
[TBL] [Abstract][Full Text] [Related]
2. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy.
Shirota Y; Stoehlmacher J; Brabender J; Xiong YP; Uetake H; Danenberg KD; Groshen S; Tsao-Wei DD; Danenberg PV; Lenz HJ
J Clin Oncol; 2001 Dec; 19(23):4298-304. PubMed ID: 11731512
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/oxaliplatin chemotherapy in advanced gastric cancer.
Kwon HC; Roh MS; Oh SY; Kim SH; Kim MC; Kim JS; Kim HJ
Ann Oncol; 2007 Mar; 18(3):504-9. PubMed ID: 17322540
[TBL] [Abstract][Full Text] [Related]
4. Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival.
Lenz HJ; Leichman CG; Danenberg KD; Danenberg PV; Groshen S; Cohen H; Laine L; Crookes P; Silberman H; Baranda J; Garcia Y; Li J; Leichman L
J Clin Oncol; 1996 Jan; 14(1):176-82. PubMed ID: 8558194
[TBL] [Abstract][Full Text] [Related]
5. Thymidylate synthase, dihydropyrimidine dehydrogenase, ERCC1, and thymidine phosphorylase gene expression in primary and metastatic gastrointestinal adenocarcinoma tissue in patients treated on a phase I trial of oxaliplatin and capecitabine.
Uchida K; Danenberg PV; Danenberg KD; Grem JL
BMC Cancer; 2008 Dec; 8():386. PubMed ID: 19105824
[TBL] [Abstract][Full Text] [Related]
6. Differential expression and prognostic value of ERCC1 and thymidylate synthase in resected gastric adenocarcinoma.
Squires MH; Fisher SB; Fisher KE; Patel SH; Kooby DA; El-Rayes BF; Staley CA; Farris AB; Maithel SK
Cancer; 2013 Sep; 119(17):3242-50. PubMed ID: 23719746
[TBL] [Abstract][Full Text] [Related]
7. ERCC1 mRNA levels and survival of advanced gastric cancer patients treated with a modified FOLFOX regimen.
Wei J; Zou Z; Qian X; Ding Y; Xie L; Sanchez JJ; Zhao Y; Feng J; Ling Y; Liu Y; Yu L; Rosell R; Liu B
Br J Cancer; 2008 Apr; 98(8):1398-402. PubMed ID: 18362936
[TBL] [Abstract][Full Text] [Related]
8. Association between ERCC1 and TS mRNA levels and disease free survival in colorectal cancer patients receiving oxaliplatin and fluorouracil (5-FU) adjuvant chemotherapy.
Li S; Zhu L; Yao L; Xia L; Pan L
BMC Gastroenterol; 2014 Aug; 14():154. PubMed ID: 25175730
[TBL] [Abstract][Full Text] [Related]
9. Messenger RNA expression of TS and ERCC1 in colorectal cancer and matched liver metastasis.
Kobayashi H; Sugihara K; Uetake H; Higuchi T; Yasuno M; Enomoto M; Iida S; Azuma M; Mori R; Omori A; Lenz HJ; Danenberg KD; Danenberg PV
Int J Oncol; 2008 Dec; 33(6):1257-62. PubMed ID: 19020759
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase pi for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer.
Kim SH; Kwon HC; Oh SY; Lee DM; Lee S; Lee JH; Roh MS; Kim DC; Park KJ; Choi HJ; Kim HJ
Am J Clin Oncol; 2009 Feb; 32(1):38-43. PubMed ID: 19194123
[TBL] [Abstract][Full Text] [Related]
11. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors.
Johnston PG; Lenz HJ; Leichman CG; Danenberg KD; Allegra CJ; Danenberg PV; Leichman L
Cancer Res; 1995 Apr; 55(7):1407-12. PubMed ID: 7882343
[TBL] [Abstract][Full Text] [Related]
12. [Effect of TUBB3, TS and ERCC1 mRNA expression on chemoresponse and clinical outcome of advanced gastric cancer by multiplex branched-DNA liquid chip technology].
Huang J; Hu H; Xie Y; Tang Y; Liu W; Zhong M
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2013 Jun; 38(6):582-9. PubMed ID: 23828702
[TBL] [Abstract][Full Text] [Related]
13. Long-term outcome of continuous 5-fluorouracil/cisplatin-based chemotherapy followed by chemoradiation in patients with resected gastric cancer.
Sonnenblick A; Rottenberg Y; Kadouri L; Wygoda M; Rivkind A; Vainer GW; Peretz T; Hubert A
Med Oncol; 2012 Dec; 29(5):3035-8. PubMed ID: 22773040
[TBL] [Abstract][Full Text] [Related]
14. Correlation between expressions of ERCC1/TS mRNA and effects of gastric cancer to chemotherapy in the short term.
Chen L; Li G; Li J; Fan C; Xu J; Wu B; Liu K; Zhang C
Cancer Chemother Pharmacol; 2013 Apr; 71(4):921-8. PubMed ID: 23355039
[TBL] [Abstract][Full Text] [Related]
15. Thymidylate synthase and ERCC1 as predictive markers in patients with pulmonary adenocarcinoma treated with pemetrexed and cisplatin.
Lee SH; Noh KB; Lee JS; Lee EJ; Min KH; Hur GY; Lee SH; Lee SY; Kim JH; Lee SY; Shin C; Shim JJ; Kim CH; Kang KH; In KH
Lung Cancer; 2013 Jul; 81(1):102-8. PubMed ID: 23523421
[TBL] [Abstract][Full Text] [Related]
16. ERCC1 predicts outcome in patients with gastric cancer treated with adjuvant cisplatin-based chemotherapy.
De Dosso S; Zanellato E; Nucifora M; Boldorini R; Sonzogni A; Biffi R; Fazio N; Bucci E; Beretta O; Crippa S; Saletti P; Frattini M
Cancer Chemother Pharmacol; 2013 Jul; 72(1):159-65. PubMed ID: 23645290
[TBL] [Abstract][Full Text] [Related]
17. ERCC1 C8092A (rs3212986) polymorphism as a predictive marker in esophageal cancer patients treated with cisplatin/5-FU-based neoadjuvant therapy.
Rumiato E; Cavallin F; Boldrin E; Cagol M; Alfieri R; Basso D; Castoro C; Ancona E; Amadori A; Ruol A; Saggioro D
Pharmacogenet Genomics; 2013 Nov; 23(11):597-604. PubMed ID: 23962907
[TBL] [Abstract][Full Text] [Related]
18. High gene expression of TS1, GSTP1, and ERCC1 are risk factors for survival in patients treated with trimodality therapy for esophageal cancer.
Joshi MB; Shirota Y; Danenberg KD; Conlon DH; Salonga DS; Herndon JE; Danenberg PV; Harpole DH
Clin Cancer Res; 2005 Mar; 11(6):2215-21. PubMed ID: 15788669
[TBL] [Abstract][Full Text] [Related]
19. Combined GADD45A and thymidine phosphorylase expression levels predict response and survival of neoadjuvant-treated gastric cancer patients.
Napieralski R; Ott K; Kremer M; Specht K; Vogelsang H; Becker K; Müller M; Lordick F; Fink U; Rüdiger Siewert J; Höfler H; Keller G
Clin Cancer Res; 2005 Apr; 11(8):3025-31. PubMed ID: 15837757
[TBL] [Abstract][Full Text] [Related]
20. Impact of excision repair cross-complementing gene 1 (ERCC1) on the outcomes of patients with advanced gastric cancer: correlative study in Japan Clinical Oncology Group Trial JCOG9912.
Yamada Y; Boku N; Nishina T; Yamaguchi K; Denda T; Tsuji A; Hamamoto Y; Konishi K; Tsuji Y; Amagai K; Ohkawa S; Fujita Y; Nishisaki H; Kawai H; Takashima A; Mizusawa J; Nakamura K; Ohtsu A
Ann Oncol; 2013 Oct; 24(10):2560-2565. PubMed ID: 23884439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
